These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 8894500)

  • 1. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
    Karara AH; Dunning BE; McLeod JF
    J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
    Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
    Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic meglitinide analogues.
    Dornhorst A
    Lancet; 2001 Nov; 358(9294):1709-16. PubMed ID: 11728565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE; Foley JE; Dunning BE
    Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
    Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
    Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
    Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
    Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
    Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
    Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
    Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
    Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.